These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23333902)

  • 1. Atorvastatin administration is associated with dose-related changes in IGF bioavailability.
    Narayanan RP; Gittins M; Siddals KW; Oliver RL; Hudson JE; White A; Durrington P; Davies RR; Rutter MK; Gibson JM
    Eur J Endocrinol; 2013 Apr; 168(4):543-8. PubMed ID: 23333902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated free IGF2 levels in localized, early-stage breast cancer in women.
    Espelund U; Cold S; Frystyk J; Ørskov H; Flyvbjerg A
    Eur J Endocrinol; 2008 Nov; 159(5):595-601. PubMed ID: 18719053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
    Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN
    Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men.
    Yeap BB; Chubb SA; Ho KK; Setoh JW; McCaul KA; Norman PE; Jamrozik K; Flicker L
    Eur J Endocrinol; 2010 Feb; 162(2):249-57. PubMed ID: 19917654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes.
    Bergen K; Brismar K; Tehrani S
    Growth Horm IGF Res; 2016 Aug; 29():78-82. PubMed ID: 27400272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of epidermal growth factor on circulating levels of free and total IGF-I and IGF-binding proteins in adult rats.
    Frystyk J; Vinter-Jensen L; Skjaerbaek C; Flyvbjerg A
    Growth Regul; 1996 Mar; 6(1):48-54. PubMed ID: 8717450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of IGF1 and IGFBPs 1 and 3 with all-cause and cardiovascular mortality in older men: the Health In Men Study.
    Yeap BB; Chubb SA; McCaul KA; Ho KK; Hankey GJ; Norman PE; Flicker L
    Eur J Endocrinol; 2011 May; 164(5):715-23. PubMed ID: 21378090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population.
    Cheng I; DeLellis Henderson K; Haiman CA; Kolonel LN; Henderson BE; Freedman ML; Le Marchand L
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3660-6. PubMed ID: 17566087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptation of ghrelin and the GH/IGF axis to high altitude.
    Riedl S; Kluge M; Schweitzer K; Waldhör T; Frisch H
    Eur J Endocrinol; 2012 Jun; 166(6):969-76. PubMed ID: 22416077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR; Sleevi M; Allan G; Sommer A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
    Huptas S; Geiss HC; Otto C; Parhofer KG
    Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients?
    Lindgren BF; Odar-Cederlöf I; Ericsson F; Brismar K
    Growth Regul; 1996 Sep; 6(3):137-43. PubMed ID: 8894646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
    Kadoglou NP; Sailer N; Kapelouzou A; Lampropoulos S; Vitta I; Kostakis A; Liapis CD
    Acta Diabetol; 2012 Aug; 49(4):269-76. PubMed ID: 21748474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IGF-system is not affected by a twofold change in protein intake in patients with type 1 diabetes.
    Hedman CA; Frystyk J; Fridell K; Jönsson A; Flyvbjerg A; Lindström T; Arnqvist HJ
    Growth Horm IGF Res; 2005 Aug; 15(4):304-10. PubMed ID: 16054412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of adiponectin multimers and the IGF axis in humans with a heterozygote mutation in the tyrosine kinase domain of the insulin receptor gene.
    Højlund K; Beck-Nielsen H; Flyvbjerg A; Frystyk J
    Eur J Endocrinol; 2012 Mar; 166(3):511-9. PubMed ID: 22189999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial.
    Ludman AJ; Hausenloy DJ; Babu G; Hasleton J; Venugopal V; Boston-Griffiths E; Yap J; Lawrence D; Hayward M; Kolvekar S; Bognolo G; Rees P; Yellon DM
    Basic Res Cardiol; 2011 Nov; 106(6):1387-95. PubMed ID: 21833652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.